secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0000950170-24-088572
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical enters exclusive distribution deal for collagen dermal matrix with Regenity Biosciences
--------------------------------------------------------------------------------

- Exclusive 5-year deal for collagen-based dermal matrix; Regenity expects 510(k) clearance in Q4 2024.
- AVITA to pay $2M upon 510(k) clearance, up to $3M more by Jan 4, 2026 contingent on clinical results.
- Revenue sharing: 50% of avg sales price first 2 years, then 60% in subsequent years.
- AVITA to commercialize under its brand in US, EU, Australia, Japan; clinical studies planned for 2025.
- CEO Jim Corbett says collaboration strengthens portfolio and may establish new standard of care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024088572/0000950170-24-088572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024088572/rcel-20240731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-088572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer